Soleno Therapeutics (NASDAQ:SLNO) Raised to “Buy” at Wall Street Zen

Soleno Therapeutics (NASDAQ:SLNO) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

SLNO has been the topic of several other reports. TD Cowen dropped their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Wells Fargo & Company lowered their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Soleno Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $106.85.

Soleno Therapeutics Price Performance

Shares of SLNO stock opened at $33.76 on Friday. Soleno Therapeutics has a twelve month low of $32.63 and a twelve month high of $90.32. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 146.79 and a beta of -3.16. The stock has a fifty day simple moving average of $40.74 and a two-hundred day simple moving average of $50.93. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after buying an additional 189 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics during the 2nd quarter worth approximately $25,000. Avanza Fonder AB raised its stake in shares of Soleno Therapeutics by 11.2% during the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after acquiring an additional 323 shares in the last quarter. Principal Financial Group Inc. lifted its position in Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after acquiring an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its position in Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after acquiring an additional 360 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.